Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective
- PMID: 38675493
- PMCID: PMC11054419
- DOI: 10.3390/ph17040533
Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective
Abstract
The TGF-β family is a group of 25 kDa secretory cytokines, in mammals consisting of three dimeric isoforms (TGF-βs 1, 2, and 3), each encoded on a separate gene with unique regulatory elements. Each isoform plays unique, diverse, and pivotal roles in cell growth, survival, immune response, and differentiation. However, many researchers in the TGF-β field often mistakenly assume a uniform functionality among all three isoforms. Although TGF-βs are essential for normal development and many cellular and physiological processes, their dysregulated expression contributes significantly to various diseases. Notably, they drive conditions like fibrosis and tumor metastasis/progression. To counter these pathologies, extensive efforts have been directed towards targeting TGF-βs, resulting in the development of a range of TGF-β inhibitors. Despite some clinical success, these agents have yet to reach their full potential in the treatment of cancers. A significant challenge rests in effectively targeting TGF-βs' pathological functions while preserving their physiological roles. Many existing approaches collectively target all three isoforms, failing to target just the specific deregulated ones. Additionally, most strategies tackle the entire TGF-β signaling pathway instead of focusing on disease-specific components or preferentially targeting tumors. This review gives a unique historical overview of the TGF-β field often missed in other reviews and provides a current landscape of TGF-β research, emphasizing isoform-specific functions and disease implications. The review then delves into ongoing therapeutic strategies in cancer, stressing the need for more tools that target specific isoforms and disease-related pathway components, advocating mechanism-based and refined approaches to enhance the effectiveness of TGF-β-targeted cancer therapies.
Keywords: TGF-β; fibrosis; oncogene; therapeutics; tumor progression.
Conflict of interest statement
The author declares no conflicts of interest.
Figures
Similar articles
-
Deciphering the functional landscape and therapeutic implications of noncoding RNAs in the TGF-β signaling pathway in colorectal cancer: A comprehensive review.Pathol Res Pract. 2024 Mar;255:155158. doi: 10.1016/j.prp.2024.155158. Epub 2024 Jan 22. Pathol Res Pract. 2024. PMID: 38320438 Review.
-
Mutual regulation between glycosylation and transforming growth factor-β isoforms signaling pathway.Int J Biol Macromol. 2023 May 1;236:123818. doi: 10.1016/j.ijbiomac.2023.123818. Epub 2023 Feb 27. Int J Biol Macromol. 2023. PMID: 36858092 Review.
-
Reevaluation of Pluripotent Cytokine TGF-β3 in Immunity.Int J Mol Sci. 2018 Aug 1;19(8):2261. doi: 10.3390/ijms19082261. Int J Mol Sci. 2018. PMID: 30071700 Free PMC article. Review.
-
Structures of TGF-β receptor complexes: implications for function and therapeutic intervention using ligand traps.Curr Pharm Biotechnol. 2011 Dec;12(12):2081-98. doi: 10.2174/138920111798808383. Curr Pharm Biotechnol. 2011. PMID: 21619540 Review.
-
Cooperation of liver cells in health and disease.Adv Anat Embryol Cell Biol. 2001;161:III-XIII, 1-151. doi: 10.1007/978-3-642-56553-3. Adv Anat Embryol Cell Biol. 2001. PMID: 11729749 Review.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources